Clinical Trials Arena on MSN

ArriVent’s stock plummets on Phase III NSCLC trial failure

ArriVent’s disappointing data comes just weeks after J&J had a successful readout in the same NSCLC patient population.
CURE

Lung Cancer Drug Misses Trial Goal, but Shows Fewer Side Effects

A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused ...

ArriVent's cancer pill fails to 'meaningfully' delay disease progression, shares dive

By Christy Santhosh Oct 6 (Reuters) - ArriVent BioPharma said on Tuesday its oral therapy to treat patients with a rare type of lung cancer did not significantly delay disease progression in a ...

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Tim…

In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival ...
Targeted Oncology

Firmonertinib Misses PFS End Point in EGFR Exon 20–Mutant NSCLC

Firmonertinib is a highly brain-penetrant, mutation-selective EGFR inhibitor with activity against classical and uncommon ...
Pharmabiz

ArriVent’s FURVENT phase 3 trial of firmonertinib in first-line EGFR Exon 20 insertion mutant NSCLC fails to meet primary endpoint

ArriVent’s FURVENT phase 3 trial of firmonertinib in first-line EGFR Exon 20 insertion mutant NSCLC fails to meet primary endpoint: Newtown Square, Pennsylvania Wednesday, Octob ...
WebMD

The EGFR-Mutated NSCLC Treatment Pipeline

Your treatment journey for non-small-cell lung cancer (NSCLC) may vary from that of others with the same diagnosis. But you’ll likely start with some of the same treatments. You’ll have lots of ...
Cancer Network

Distinguishing HER2 Mutations From Amplification in NSCLC Testing

Xiuning Le, MD, PhD, explains how oncologists should approach HER2 biomarker testing following sevabertinib’s frontline approval in non–small cell lung cancer. Xiuning Le, MD, PhD, an associate ...